加州 的 下咽癌 臨床試驗
7 項針對 下咽癌 的研究正在 加州 各地點尋找參與者。
加州 的城市
官方研究文本（英文）
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- VA Palo Alto Health Care System, Palo Alto
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年10月1日 · NCT06589804BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Tower Cancer Research Foundation, Beverly Hills
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
- 還有 4 項
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月25日 · NCT05136196Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
- Mercy Cancer Center - Carmichael, Carmichael
- 還有 11 項
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月14日 · NCT02734537Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
- City of Hope Comprehensive Cancer Center, Duarte
- City of Hope at Irvine Lennar, Irvine
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年9月3日 · NCT07156227Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- UC San Diego Health System - Encinitas, Encinitas
- UC San Diego Moores Cancer Center, La Jolla
- UC San Diego Medical Center - Hillcrest, San Diego
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年8月17日 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
- Tower Cancer Research Foundation, Beverly Hills
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年8月17日 · NCT07441681Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- City of Hope, Duarte
- Los Angeles Cancer Network, Glendale
- California Research Institute, Los Angeles
- 還有 3 項
招募中1/2 期
18 歲及以上 · 所有性別 · 更新於 2026年7月29日 · NCT04198766資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。